Work

Preliminary analysis of disitamab vedotin combined therapy for HER2-expressing platinum-sensitive recurrent ovarian/peritoneal/fallopian tube cancer (Diversity study): A single-arm, multicenter phase II trial.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.5564

Authors: Tong Shu, Hong Zheng, Kui Jiang, Fang Liu, Hongruo Liu, Lu lu Yao, Ye Zhao, Ying Ma, Yan Zhang, Guihua Shen, Linlin Ma

Institutions: Peking University Cancer Hospital, Dalian Medical University, Second Affiliated Hospital of Dalian Medical University, Shanxi Medical University, First Hospital of Shanxi Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Hospital

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410813008

Cites:

Cited by: 1

Related to: 10